In a bid to detect cancers early and in a noninvasive way, scientists at the Johns Hopkins Kimmel Cancer Center report they have developed a test that spots tiny amounts of cancer-specific DNA in blood and have used it to accurately identify more than half of 138 people with relatively early-stage colorectal, breast, lung and ovarian cancers. The test, the scientists say, is novel in that it can distinguish between DNA shed from tumors and other altered DNA that can be mistaken for cancer biomarkers.
A report on the research, performed on blood and tumor tissue samples from 200 people with all stages of cancer in the U.S., Denmark and the Netherlands, appears in the Aug. 16 issue of Science Translational Medicine.
“This study shows that identifying cancer early using DNA changes in the blood is feasible and that our high accuracy sequencing method is a promising approach to achieve this goal,” says Victor Velculescu, M.D., Ph.D., professor of oncology at the Johns Hopkins Kimmel Cancer Center.
Blood tests for cancer are a growing part of clinical oncology, but they remain in the early stages of development. To find small bits of cancer-derived DNA in the blood of cancer patients, scientists have frequently relied on DNA alterations found in patients’ biopsied tumor samples as guideposts for the genetic mistakes they should be looking for among the masses of DNA circulating in those patients’ blood samples.
To develop a cancer screening test that could be used to screen seemingly healthy people, scientists had to find novel ways to spot DNA alterations that could be lurking in a person’s blood but had not been previously identified.
“The challenge was to develop a blood test that could predict the probable presence of cancer without knowing the genetic mutations present in a person’s tumor,” says Velculescu.
The goal, adds Jillian Phallen, a graduate student at the Johns Hopkins Kimmel Cancer Center who was involved in the research, was to develop a screening test that is highly specific for cancer and accurate enough to detect the cancer when present, while reducing the risk of “false positive” results that often lead to unnecessary overtesting and overtreatments.
The task is notably complicated, says Phallen, by the need to sort between true cancer-derived mutations and genetic alterations that occur in blood cells and as part of normal, inherited variations in DNA.
As blood cells divide, for example, Velculescu says there is a chance these cells will acquire mistakes or mutations. In a small fraction of people, these changes will spur a blood cell to multiply faster than its neighboring cells, potentially leading to pre-leukemic conditions. However, most of the time, the blood-derived mutations are not cancer-initiating.
His team also ruled out so-called “germline” mutations. While germline mutations are indeed alterations in DNA, they occur as a result of normal variations between individuals, and are not usually linked to particular cancers.
To develop the new test, Velculescu, Phallen and their colleagues obtained blood samples from 200 patients with breast, lung, ovarian and colorectal cancer. The scientists’ blood test screened the patients’ blood samples for mutations within 58 genes widely linked to various cancers.
Overall, the scientists were able to detect 86 of 138 (62 percent) stage I and II cancers. More specifically, among 42 people with colorectal cancer, the test correctly predicted cancer in half of the eight patients with stage I disease, eight of nine (89 percent) with stage II disease, nine of 10 (90 percent) with stage III and 14 of 15 (93 percent) with stage IV disease. Of 71 people with lung cancer, the scientists’ test identified cancer among 13 of 29 (45 percent) with stage I disease, 23 of 32 (72 percent) with stage II disease, three of four (75 percent) with stage III disease and five of six (83 percent) with stage IV cancer. For 42 patients with ovarian cancer, 16 of 24 (67 percent) with stage I disease were correctly identified, as well as three of four (75 percent) with stage II disease, six of eight (75 percent) with stage III cancer and five of six (83 percent) with stage IV disease. Among 45 breast cancer patients, the test spotted cancer-derived mutations in two of three (67 percent) patients with stage I disease, 17 of 29 (59 percent) with stage II disease and six of 13 (46 percent) with stage III cancers.
They found none of the cancer-derived mutations among blood samples of 44 healthy individuals.
Despite these initial promising results for early detection, the blood test needs to be validated in studies of much larger numbers of people, say the scientists.
Velculescu and his team also performed independent genomic sequencing on available tumors removed from 100 of the 200 patients with cancer and found that 82 (82 percent) had mutations in their tumors that correlated with the genetic alterations found in the blood.
The Johns Hopkins-developed blood test uses a type of genomic sequencing the researchers call “targeted error correction sequencing.” The sequencing method is based on deep sequencing, which reads each chemical code in DNA 30,000 times. “We’re trying to find the needle in the haystack, so when we do find a DNA alteration, we want to make sure it is what we think it is,” says Velculescu.
Such deep sequencing, covering more than 80,000 base pairs of DNA, has the potential to be very costly, but Velculescu says sequencing technology is becoming cheaper, and his research team may eventually be able to reduce the number of DNA locations they screen while preserving the test’s accuracy.
He says the populations that could benefit most from such a DNA-based blood test include those at high risk for cancer including smokers — for whom standard computed tomography scans for identifying lung cancer often lead to false positives — and women with hereditary mutations for breast and ovarian cancer within BRCA1 and BRCA2 genes.
The Latest on: Cancer detection
- Breast Cancer Diagnosis Prompts Survivor to Take Care of Herself on September 19, 2017 at 7:26 am
Hashmat Effendi has spent more than 20 years helping children all over the world get medical care that they otherwise couldn’t afford for burns, injuries, and birth defects. “I’m originally from Pakistan, and I saw first-hand the struggles of poor ... […]
- Home and Away star Johnny Ruffo makes first red carpet appearance since brain cancer diagnosis on September 19, 2017 at 5:17 am
Former Home and Away star Johnny Ruffo has made his first red carpet appearance since announcing the sad news that he has a cancerous brain tumour. 29-year-old Johnny, who played Chris Harrington on Home and Away, underwent an emergency operation to remove ... […]
- Awareness Campaign Takes Lung Cancer Risk Head-On, Asking North Carolinians To Screen Together on September 19, 2017 at 5:09 am
encourages those at risk for lung cancer to get screened along with a friend or loved one who may also be at risk. Early detection of lung cancer through screening can dramatically increase survival for those at risk of the disease. At least 8.6 million ... […]
- Women Say 'Cancer Casanova' Made Up Terminal Diagnosis for Sympathy and Money: 'He Broke Me' on September 18, 2017 at 2:02 pm
It’s a love story like you’ve never heard before. Ken Boyer, who says he was diagnosed with terminal cancer, was granted his dying wish to marry his long lost love Michelle after they reconnected on Facebook earlier this year. Read: Ex-Beauty Queen ... […]
- Early Detection and HERA Helped Me Arrest the Spread of Breast Cancer on September 18, 2017 at 7:41 am
As the daughter and great-grand-daughter of breast cancer survivors, I knew I was at increased risk of developing breast cancer. My Ashkenazi Jewish heritage also increased the likelihood I would develop cancer in my lifetime. But I had heard once breast ... […]
- ITUS Corporation Announces Issuance of Patent on Cancer Detection Technology on September 18, 2017 at 6:30 am
SAN JOSE, CA--(Marketwired - September 18, 2017) - ITUS Corporation (NASDAQ: ITUS), today announced that the United States Patent and Trademark Office ("USPTO") has issued U.S. Patent 9,739,783, to inventors Dr. Amit Kumar, Chief Executive Officer, and ... […]
- Brain Cancer Symptoms And Treatment Explained Following Dame Tessa Jowell's Diagnosis on September 18, 2017 at 5:55 am
The family of Dame Tessa Jowell, the former Labour Cabinet minister, have revealed she is undergoing treatment for brain cancer. On Instagram, Jowell’s daughter-in-law Ella Mills, better known by her blogger name Deliciously Ella, revealed the ex-Culture ... […]
- 'Growing Pains' star Joanna Kerns underwent a double mastectomy after breast cancer diagnosis on September 18, 2017 at 5:21 am
Joanna Kerns is opening up about her double mastectomy after a scary breast cancer diagnosis. The 64-year-old actress, best known for starring as Maggie Malone Seaver on “Growing Pains,” was recently “given an all clear” after the surgery. […]
- Breast cancer diagnosis can't stop her on September 17, 2017 at 9:29 pm
Editor's note: This story is part of a series that is published for Project Self-Sufficiency's "Mammograms Save Lives" program. When she was diagnosed with breast cancer at the age of 62, Debbie Papanestor had only one question for the physician who had ... […]
- Firehouse Puts Down Second K-9 in a Year After Cancer Diagnosis: 'He Gave Up His Life to Volunteer' on September 16, 2017 at 4:36 pm
For the second time in a year, this New Jersey fire department held a hero’s salute for their beloved K-9 dog as he was being put down. Read: Elderly K-9 Officer Receives Hero's Salute Before Being Put Down: 'He Was Family' Timmy, the 11-year-old German ... […]
via Google News and Bing News